How to prevent multidrug-resistant tuberculosis?

Hi,

Welcome to icliniq.com.

I understand your concern.

Let me first explain regular tuberculosis (TB). It is caused by Mycobacterium tuberculosis, treatable with a standard regimen of first-line antibiotics (usually Isoniazid and Rifampicin, along with Pyrazinamide and Ethambutol).

Multidrug-resistant tuberculosis (MDR-TB) is caused by strains of Mycobacterium tuberculosis resistant to at least Isoniazid and Rifampicin, the two most potent TB drugs. This resistance makes MDR-TB more difficult and costly to treat, requiring second-line drugs, which are often less effective, more toxic, and require longer treatment durations.

Contributions of Onno Akkerman:

Onno Akkerman is a recognized expert in the field of tuberculosis with contributions as follows:

1. Research on diagnostic methods: Akkerman has worked on improving diagnostic techniques for TB and MDR-TB, enabling earlier and more accurate detection of drug-resistant strains.

2. Treatment protocols: He has been involved in developing and refining treatment protocols to manage MDR-TB more effectively, aiming to improve patient outcomes and reduce transmission.

3. Publications and guidelines: Akkerman has published extensively on TB and MDR-TB, contributing to the body of knowledge and informing clinical guidelines.

Antibiotic Treatment for MDR-TB MDR-TB involves second-line drugs such as Fluoroquinolones (e.g., Levofloxacin, Moxifloxacin) and injectable agents (e.g., Amikacin, Capreomycin). Treatment typically lasts 18 to 24 months, compared to six to nine) months for drug-sensitive TB. However, treatment is associated with a variety of challenges such as:

1. Side effects: Second-line drugs often have severe side effects, including kidney damage, hearing loss, and psychiatric disorders.

2. Adherence: The lengthy and complex treatment regimen makes adherence difficult, increasing the risk of treatment failure and further resistance.

3. Cost: Treatment for MDR-TB is significantly more expensive than for drug-sensitive TB.

4. Limited availability: Access to second-line drugs and necessary medical infrastructure is limited in many regions, especially in low-income countries.

Best practices for preventing the spread of MDR-TB include:

1. Early detection and treatment: Rapid diagnosis and initiation of appropriate treatment to prevent transmission.

2. Adherence support: Providing support for patients to complete their treatment regimen, such as through directly observed therapy (DOT).

3. Infection control: Implementing stringent infection control measures in healthcare settings, including isolation of infectious patients.

4. Public health education: Raising awareness about TB and the importance of completing treatment.

5. Vaccination: Promoting the use of the BCG (Bacillus Calmette–Guerin) vaccine where appropriate, especially in high-risk populations.

New developments and promising treatments include:

1. New antibiotics: Bedaquiline and Delamanid. Newer drugs that have shown effectiveness against MDR-TB and are included in treatment regimens to improve outcomes.

2. Shorter regimens: Research is ongoing to develop shorter, more effective treatment regimens to improve patient adherence and reduce side effects.

3. Diagnostic advances: Improved diagnostic tools, such as GeneXpert MTB/RIF, which can rapidly detect TB and Rifampicin resistance.

4. Host-directed therapies: Approaches that enhance the patient’s immune response to TB, potentially improving treatment outcomes.

5. Vaccine development: Several new TB vaccines are in development, aiming to provide better protection against TB and its drug-resistant forms.

I hope this answers your queries.

Let me know if you have any other concerns.

Regards.